PSK Pharma, the largest resident of the pharmaceutical cluster of the Dubna special Economic Zone, is developing eight drugs for the treatment of asthma and chronic obstructive pulmonary disease (COPD). This was reported by the press service of the Ministry of Investments, Industry, and Science of the Moscow Region.
The company’s portfolio includes 25 pulmonological drugs, five of which have been reproduced in Russia for the first time. Furthermore, according to the press service, “eight more drugs for the treatment of chronic bronchopulmonary diseases are at various stages of development.”
This year, PSK Pharma doubled its production capacity for capsules with powder for inhalation and launched the first domestic dual bronchodilator combining glycopyrronium bromide with indacaterol. To date, dual bronchodilators are the most in-demand class of drugs for treating COPD and form the foundation of therapy for this disease.
As previously reported, the medical and pharmaceutical cluster of the Dubna economic zone includes 45 companies. They have already invested more than 32 billion rubles in their projects. Cluster residents will also produce hemostatic agents, anticancer drugs, medications for stabilizing blood pressure, and beta-lactam antibiotics.
About a month ago, Ginatech, a subsidiary of the pharmaceutical manufacturer Pharmasyntez, launched the production of bronchodilators worth 1 billion rubles at its plant in Irkutsk. The product line will include approximately 25 drugs, which is expected to allow the company to capture about a quarter of this market segment in 2026-2027.
